With the emergence of precision medicine, biomarkers have advanced from being exploratory endpoints to operating as clinical trial assays under fit-for-purpose validations to serve as inclusion and exclusion criteria. Genomic insights play a crucial role in the development of companion diagnostics (CDx) to support precision therapeutics. However, clinically meaningful, actionable mutations occur at very low frequency and securing biospecimens with those mutations is challenging.
Rob Fannon, General Manager for Biospecimen Solutions at Precision for Medicine, delivered a presentation entitled Advancing CDx Development with a Novel Next Generation Sequencing Initiative at the Association for Molecular Pathology Annual Meeting - AMP 2021. Precision for Medicine, a global leader in supplying biospecimens, lab services, and CRO services to the life sciences industries, was pleased to have Fannon share his strategic insights with the AMP audience.